SRRK

Scholar Rock Holding Corp

NasdaqAdd to watchlist

Healthcare · Biotechnology

$46.65

−$2.37−4.83%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

11 of 29 open-market sales on file ran under a pre-arranged trading plan ($8.86M), 18 did not. Who, and when

Aug 24, 2026$46.65

−$11.55−19.85%over 1M

Session

Day range29% of range

$45.88$48.53

Fundamentals

Visualize fundamentals and more

Market cap: 6.09B
P/E ratio: -

Risk factors, year on year

Item 1AMar 2026 10-KFeb 2025

added: 56
dropped: 63
re-drafted: 66

Out of 294 passages in this year’s Item 1A.

New this year

● The regulatory approval process for apitegromab in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, or we may receive …

118 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Data privacy
Litigation
Export controls
Product recalls
Tariffs
Russia and Ukraine

And 11 more.

FDA approval
Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates. 57 Table of Contents ● The results of …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Scholar Rock Holding Corp investor relations

What SRRK has filed with the SEC. This is not Scholar Rock Holding Corp’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Scholar Rock Holding Corp

Also filed under Biotechnology, ranked by how closely they sit beside SRRK.

MRNAModerna, Inc.compare with SRRK
ROIVRoivant Sciences Ltd.compare with SRRK
VRTXVertex Pharmaceuticals Inc. / MA

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Data privacy
Litigation
Export controls
Product recalls
Tariffs
Russia and Ukraine

And 11 more.

FDA approval
Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates. 57 Table of Contents ● The results of …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

XENEXenon Pharmaceuticals Inc.compare with SRRK

NVONovo Nordisk A Scompare with SRRK

Ask about Scholar Rock Holding Corp

The assistant answers from what SRRK has actually filed: 9 annual reports filed with the SEC, 81 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from SRRK's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Scholar Rock Holding Corp each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Scholar Rock Holding Corp

Be told the moment a SRRK insider trades
Put Scholar Rock Holding Corp on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Scholar Rock Holding Corp's income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Scholar Rock Holding Corp's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Risk factors, year on year

Item 1AMar 2026 10-KFeb 2025

added: 56
dropped: 63
re-drafted: 66

Out of 294 passages in this year’s Item 1A.

New this year

● The regulatory approval process for apitegromab in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, or we may receive …

118 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

19 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add